Trial Profile
A Pilot Study of Neoadjuvant SUNITINIB MALATE (Sunitinib) in Patients With Renal Cell Carcinoma Undergoing Nephrectomy.
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 26 Sep 2012
Price :
$35
*
At a glance
- Drugs Sunitinib (Primary)
- Indications Renal cell carcinoma
- Focus Adverse reactions
- 21 Sep 2011 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 21 Sep 2011 Actual end date (Apr 2010) added as reported by ClinicalTrials.gov.
- 09 Jul 2009 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.